Table 2

Mean changes in disease activity from baseline to week 12 by treatment group

Baseline to week 12
Adalimumab (n=19)Placebo (n=19)p Value
Patient's global assessment, 0–100 mm VAS–31.0 (23.3)–5.9 (21.4)0.001
Physician's global assessment, 0–100 mm VAS–19.8 (19.5)–4.1 (16.4)0.007
Swollen joint count, 0–66 joints–2.5 (4.0)–0.4 (1.8)0.291
Tender joint count, 0–68 joints–1.8 (9.2)1.7 (6.5)0.202
BASDAI–1.8 (2.6)–0.3 (1.5)0.024
ASDAS–1.1 (1.2)–0.0 (0.9)0.001
CRP, mg/l–5.7 (12.4)4.0 (22.9)0.071
ESR, mm/h–6.0 (12.5)1.7 (9.3)0.015
  • Values are the mean change (SD) from baseline to week 12. Significance of the comparisons is determined by analysis of covariance (ANCOVA) adjusted for baseline, comparing adalimumab with placebo treatment.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale.